《新股表现》嘉和生物-B(06998.HK)暗盘高开50%报36元
根据辉立交易平台显示,明天挂牌的嘉和生物-B(06998.HK)暗盘高开50%报36元,高低见38.15/34.8元,现造36.3元,较上市价24元,高51%,成交459万股。
嘉和是一家正在进入商业化阶段仍未录得盈利的生物制药公司,其专注於肿瘤及自身免疫药物的研发及商业化,而一直在研发的候选药物涵盖全球前三大肿瘤靶标及十款最畅销药物中的五款。
是次在港上市共发售近1.2亿股,并已引入高瓴资本、淡马?旗下Aranda Investments、泰格医药(03347.HK)及云峰金融(00376.HK)旗下万通保险及中国平安(02318.HK)等12名基石投资者合共认购5,994万股;10%公开发售获1,246.5倍超购,已启动回拨机制占比增至50%,认购一手中签率仅3%;股份以招股范围(20.3-24元)上限定价,料集资净额约26.94亿元,主要用於为核心产品及其他主要产品研发活动提供资金、拨付研发中其他候选药物正在进行及计划中临床试验、适应症扩展及注册案筹备,以及用於为药物管线扩展提供资金等。上市联席保荐人分别为高盛、摩通及富瑞。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.